Literature DB >> 18268091

Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.

Anne J Lenaerts1, Casey Bitting, Lisa Woolhiser, Veronica Gruppo, Karen S Marietta, Christine M Johnson, Ian M Orme.   

Abstract

A novel subclass of quinolones, 2-pyridones, showed potent activity against Mycobacterium tuberculosis, with KRQ-10018 being an early lead. KRQ-10018 showed better activity in vitro against M. tuberculosis versus moxifloxacin. In vivo efficacy of KRQ-10018 at 300 mg/kg of body weight was similar to that of isoniazid at 25 mg/kg, but showed less activity than moxifloxacin at 300 mg/kg.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18268091      PMCID： PMC2292560          DOI： 10.1128/AAC.00897-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.

Authors:  Yanmin Hu; Anthony R M Coates; Denis A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

2.  Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth.

Authors:  R J Wallace; D R Nash; L C Steele; V Steingrube
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

3.  Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.

Authors:  B P Kelly; S K Furney; M T Jessen; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

4.  Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.

Authors:  L Collins; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.

Authors:  G Kubendiran; C N Paramasivan; S Sulochana; D A Mitchison
Journal:  J Chemother       Date:  2006-12       Impact factor: 1.714

6.  Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.

Authors:  Anne J Lenaerts; Veronica Gruppo; Karen S Marietta; Christine M Johnson; Diane K Driscoll; Nicholas M Tompkins; Jerry D Rose; Robert C Reynolds; Ian M Orme
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 7.  The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors.

Authors:  Q Li; L A Mitscher; L L Shen
Journal:  Med Res Rev       Date:  2000-07       Impact factor: 12.944

8.  Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

Authors:  Eric L Nuermberger; Tetsuyuki Yoshimatsu; Sandeep Tyagi; Richard J O'Brien; Andrew N Vernon; Richard E Chaisson; William R Bishai; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2003-10-24       Impact factor: 21.405

9.  Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice.

Authors:  Anne J M Lenaerts; Veronica Gruppo; Jason V Brooks; Ian M Orme
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.

Authors:  Eric L Nuermberger; Tetsuyuki Yoshimatsu; Sandeep Tyagi; Kathy Williams; Ian Rosenthal; Richard J O'Brien; Andrew A Vernon; Richard E Chaisson; William R Bishai; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2004-08-11       Impact factor: 21.405
View more
  6 in total

Review 1.  Transferable Mechanisms of Quinolone Resistance from 1998 Onward.

Authors:  Joaquim Ruiz
Journal:  Clin Microbiol Rev       Date:  2019-08-14       Impact factor: 26.132

2.  MenA is a promising drug target for developing novel lead molecules to combat Mycobacterium tuberculosis.

Authors:  Michio Kurosu; Dean C Crick
Journal:  Med Chem       Date:  2009-03       Impact factor: 2.745

3.  Discovery and validation of new antitubercular compounds as potential drug leads and probes.

Authors:  Robert C Goldman; Barbara E Laughon
Journal:  Tuberculosis (Edinb)       Date:  2009-08-28       Impact factor: 3.131

Review 4.  What animal models teach humans about tuberculosis.

Authors:  Ashwin S Dharmadhikari; Edward A Nardell
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-12       Impact factor: 6.914

5.  Identification of novel Mt-Guab2 inhibitor series active against M. tuberculosis.

Authors:  Veeraraghavan Usha; Judith V Hobrath; Sudagar S Gurcha; Robert C Reynolds; Gurdyal S Besra
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

Review 6.  The current state of animal models and genomic approaches towards identifying and validating molecular determinants of Mycobacterium tuberculosis infection and tuberculosis disease.

Authors:  Allison N Bucsan; Smriti Mehra; Shabaana A Khader; Deepak Kaushal
Journal:  Pathog Dis       Date:  2019-06-01       Impact factor: 3.166
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.